Product Description
AMG 811is a human IgG1 monoclonal antibody that selectively targets and neutralizes human IFN- g.
Mechanisms of Action: IFNG Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Glomerulonephritis|Lupus Erythematosus, Systemic|Lupus Nephritis|Lupus Erythematosus, Discoid|Lupus Erythematosus, Cutaneous|Psoriasis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT00818948 | P1 |
Completed |
Lupus Nephritis|Glomerulonephritis|Lupus Erythematosus, Systemic |
2014-06-01 |
|
| NCT01510951 | P1 |
Completed |
Psoriasis |
2012-10-01 |
|
| NCT01164917 | P1 |
Terminated |
Lupus Erythematosus, Discoid|Lupus Erythematosus, Cutaneous|Lupus Erythematosus, Systemic |
2012-09-01 |
|
| NCT02291588 | P1 |
Completed |
Lupus Erythematosus, Systemic |
2010-03-01 |